{"analyses":[{"ciLowerLimit":"-4.2","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.0","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7570","paramType":"Mean Difference (Net)","paramValue":"-0.6","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.9","upperLimit":"1.6","value":"-1.2"},{"groupId":"OG001","lowerLimit":"-3.0","upperLimit":"1.8","value":"-0.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Change in Neuropathy Impairment Score-Lower Limb (NIS-LL) Total Score in subjects with peripheral nerve involvement. NIS-LL is a scoring system graduated from 0 points to a maximum of 88 points (the absence of all motor, sensory, and reflex activity in the lower extremities). The scale is an additive of all deficits (64 potential points for muscle strength, 8 points for reflexes, and 16 points for sensory function) in the lower extremities. A score of 0 is normal and score of 88 is total impairment.","dispersionType":"95% Confidence Interval","groups":[{"description":"NEOD001, 24 mg/kg IV every 4 weeks for 12 months","id":"OG000","title":"NEOD001 24 mg/kg"},{"description":"Placebo, 0.9% Saline IV every 4 weeks for 12 months","id":"OG001","title":"Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Peripheral Neuropathy Evaluable Population","reportingStatus":"POSTED","timeFrame":"Baseline to 12 months of treatment","title":"NIS-LL Total Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}